Income Statement
MIRA PHARMACEUTICALS, INC.
MIRA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
- | - | - |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
- | - | - |
|
Operating Expenses
|
10.49 | 8.02 | 8.53 |
|
Research & Development
|
1.72 | 3.31 | 1.57 |
|
Selling, General & Administrative
|
8.77 | 4.71 | 6.50 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-10.49 | -8.02 | -8.53 |
|
Non-Operating Income
|
0.05 | - | - |
|
Interest Income
|
- | - | - |
|
Interest Expense
|
- | -0.17 | 3.46 |
|
Other Non-Op Income / Expense
|
0.05 | - | - |
|
Income Before Tax
|
- | - | - |
|
Income Tax Expense
|
- | - | - |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-10.44 | -7.85 | -11.98 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-10.49 | -8.02 | -8.53 |
|
Earnings Per Share (Basic)
|
-1.35 | -0.51 | -0.64 |
|
Diluted EPS
|
-1.35 | -0.51 | -0.64 |
|
Weighted Average Shares
|
23.69 | 15.44 | 18.57 |
|
Diluted Weighted Avg Shares
|
- | 15.44 | 18.57 |
|
Comprehensive Income
|
- | - | - |